b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">31640607</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>02</Month>\n            <Day>26</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>02</Month>\n            <Day>26</Day>\n        </DateRevised>\n        <Article PubModel="Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1471-2407</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>19</Volume>\n                    <Issue>1</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>Oct</Month>\n                        <Day>22</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>BMC cancer</Title>\n                <ISOAbbreviation>BMC Cancer</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>977</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-019-6220-1</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Conventionally fractionated (CF) radiation therapy (RT) has been associated with lymphopenia, leading to compromised overall survival (OS) in cancer patients. It currently remains unknown if stereotactic body (SB) RT induces lymphopenia to the same degree. The aim of this study is to determine if SBRT with either chemotherapy (CMT) (Fluorouracil (5FU) or capecitabine) or Nelfinavir (NFV) to pancreatic adenocarcinoma induces lymphopenia to the same degree as CFRT with 5FU or capecitabine and how any associated difference affects patient survival outcomes.</AbstractText>\n                <AbstractText Label="METHODS" NlmCategory="METHODS">Medical records of pancreatic adenocarcinoma patients treated with induction CMT followed by RT with concurrent CMT or NFV\xc2\xa0were reviewed. Patients with total lymphocyte counts (TLCs) available both prior to and following initiation of RT were included. Three groups were identified: CFRT/CMT, SBRT/CMT, and SBRT/NFV. Median delivered RT doses for CFRT and SBRT were 50.4\xe2\x80\x89Gy in 1.8\xe2\x80\x89Gy fractions and 35\xe2\x80\x89Gy in 7\xe2\x80\x89Gy fractions, respectively. TLCs from day 0 (the first day of RT) to 40 were recorded and analyzed using the Kruskal-Wallis test with p-values adjusted with Bonferroni\'s method. Linear regressions were utilized to estimate the slope of TLCs as it changes with time and survival analysis was performed via Kaplan-Meier plots.</AbstractText>\n                <AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred patients were identified (28 CFRT/CMT, 27 SBRT/CMT, 45 SBRT/NFV). Median pre-RT TLCs were not different among groups. Median lowest TLCs were significantly lower (p\xc2\xa0&lt;\xe2\x80\x89\xc2\xa00.0001) and median TLCs reduction over time were significantly greater (p\xe2\x80\x89&lt;\xe2\x80\x89\xc2\xa00.0001) in the CFRT group than SBRT groups. There was no difference in lowest TLCs or TLCs reduction over time between SBRT groups. Across all groups, the median time to lowest TLCs was similar. Survival analysis revealed no significant difference in median OS between SBRT and CFRT groups. However, in patients with surgery, Median OS for patients with SBRT/CMT was significantly higher than in those with SBRT/NFV (p\xc2\xa0=\xe2\x80\x890.03).</AbstractText>\n                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Compared to CFRT, SBRT is associated with less lymphopenia. Further study of the effect of radiation technique on immune status is warranted.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Wu</LastName>\n                    <ForeName>Guangyin</ForeName>\n                    <Initials>G</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, Henan Provincial People\'s Hospital; People\'s Hospital of Zhengzhou University, Henan, China.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, University of Nebraska Medical Center, 986861 Nebraska Medical Center, Omaha, NE, 68198-68618, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Baine</LastName>\n                    <ForeName>Michael J</ForeName>\n                    <Initials>MJ</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, University of Nebraska Medical Center, 986861 Nebraska Medical Center, Omaha, NE, 68198-68618, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhao</LastName>\n                    <ForeName>Nan</ForeName>\n                    <Initials>N</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, University of Nebraska Medical Center, 986861 Nebraska Medical Center, Omaha, NE, 68198-68618, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Li</LastName>\n                    <ForeName>Sicong</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, University of Nebraska Medical Center, 986861 Nebraska Medical Center, Omaha, NE, 68198-68618, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Li</LastName>\n                    <ForeName>Xiaobo</ForeName>\n                    <Initials>X</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China. lixiaobo2004@126.com.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>College of Medical Technology and Engineering, Fujian Medical University, Fuzhou, Fujian, China. lixiaobo2004@126.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lin</LastName>\n                    <ForeName>Chi</ForeName>\n                    <Initials>C</Initials>\n                    <Identifier Source="ORCID">http://orcid.org/0000-0002-7279-0473</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, University of Nebraska Medical Center, 986861 Nebraska Medical Center, Omaha, NE, 68198-68618, USA. clin@unmc.edu.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>2 P50 CA127297-06A1</GrantID>\n                    <Agency>DHHS/NIH/NCI</Agency>\n                    <Country/>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D003160">Comparative Study</PublicationType>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>10</Month>\n                <Day>22</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>BMC Cancer</MedlineTA>\n            <NlmUniqueID>100967800</NlmUniqueID>\n            <ISSNLinking>1471-2407</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>6804DJ8Z9U</RegistryNumber>\n                <NameOfSubstance UI="D000069287">Capecitabine</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>HO3OGH5D7I</RegistryNumber>\n                <NameOfSubstance UI="D019888">Nelfinavir</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>U3P01618RT</RegistryNumber>\n                <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n                <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000964" MajorTopicYN="N">Antimetabolites, Antineoplastic</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000069287" MajorTopicYN="N">Capecitabine</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D059248" MajorTopicYN="N">Chemoradiotherapy</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D019583" MajorTopicYN="N">Dose Fractionation, Radiation</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D060828" MajorTopicYN="N">Induction Chemotherapy</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D018655" MajorTopicYN="N">Lymphocyte Count</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>\n                <QualifierName UI="Q000528" MajorTopicYN="Y">radiation effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008231" MajorTopicYN="Y">Lymphopenia</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D019888" MajorTopicYN="N">Nelfinavir</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n                <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016634" MajorTopicYN="N">Radiosurgery</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Lymphocyte-sparing</Keyword>\n            <Keyword MajorTopicYN="N">Pancreatic cancer</Keyword>\n            <Keyword MajorTopicYN="N">SBRT</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>01</Month>\n                <Day>04</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>09</Month>\n                <Day>30</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>10</Month>\n                <Day>24</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>10</Month>\n                <Day>24</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>2</Month>\n                <Day>27</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>epublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31640607</ArticleId>\n            <ArticleId IdType="doi">10.1186/s12885-019-6220-1</ArticleId>\n            <ArticleId IdType="pii">10.1186/s12885-019-6220-1</ArticleId>\n            <ArticleId IdType="pmc">PMC6805585</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Ann Surg Oncol. 2011 May;18(5):1319-26</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21499862</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Head Neck. 2014 Dec;36(12):1747-53</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24174270</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2010 Oct 10;28(29):4450-6</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20837948</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Invest. 2013 Feb;31(2):140-4</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23362951</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Neurooncol. 2016 Apr;127(2):329-35</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26725885</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2005 Jul 10;23(20):4538-44</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16002845</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Therap Adv Gastroenterol. 2017 Jan;10(1):168-194</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28286568</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2008 Jun 1;26(16):2699-706</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18509182</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):571-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26867885</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):323-332</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28068240</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Semin Radiat Oncol. 2014 Apr;24(2):140-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24635871</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Natl Compr Canc Netw. 2015 Oct;13(10):1225-31</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26483062</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>CNS Oncol. 2012 Nov;1(2):149-54</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23828734</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Invest. 2013 Mar;31(3):183-8</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23432821</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Invest. 2012 Oct;30(8):571-6</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22812722</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Gynecol Oncol. 2016 Jan;140(1):76-82</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26571200</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'